A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs GSK 3359609 (Primary) ; Tremelimumab (Primary) ; Cetuximab; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Dec 2018 Planned End Date changed from 23 Jun 2022 to 16 Jun 2022.
- 10 Dec 2018 Planned primary completion date changed from 23 Jun 2022 to 16 Jun 2022.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.